CA3165166A1 - Rar-alpha compounds for inflammatory disease and male contraception - Google Patents
Rar-alpha compounds for inflammatory disease and male contraceptionInfo
- Publication number
- CA3165166A1 CA3165166A1 CA3165166A CA3165166A CA3165166A1 CA 3165166 A1 CA3165166 A1 CA 3165166A1 CA 3165166 A CA3165166 A CA 3165166A CA 3165166 A CA3165166 A CA 3165166A CA 3165166 A1 CA3165166 A1 CA 3165166A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950473P | 2019-12-19 | 2019-12-19 | |
| US62/950,473 | 2019-12-19 | ||
| PCT/US2020/065719 WO2021127250A1 (en) | 2019-12-19 | 2020-12-17 | Rar-alpha compounds for inflammatory disease and male contraception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3165166A1 true CA3165166A1 (en) | 2021-06-24 |
Family
ID=74186909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3165166A Pending CA3165166A1 (en) | 2019-12-19 | 2020-12-17 | Rar-alpha compounds for inflammatory disease and male contraception |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12492177B2 (https=) |
| EP (1) | EP4077300A1 (https=) |
| JP (1) | JP7657223B2 (https=) |
| CN (1) | CN115335367B (https=) |
| AU (1) | AU2020408043A1 (https=) |
| CA (1) | CA3165166A1 (https=) |
| WO (1) | WO2021127250A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492177B2 (en) | 2019-12-19 | 2025-12-09 | Orphagen Pharmaceuticals, Inc. | RAR-α compounds for inflammatory disease and male contraception |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US6521641B1 (en) * | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
| AU757448B2 (en) | 1998-10-08 | 2003-02-20 | Allergan, Inc. | Male anti-fertility agents |
| US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
| US7105566B2 (en) * | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
| DK3204357T3 (da) | 2014-10-10 | 2022-04-04 | High Force Res Limited | Fluorescerende, syntetiske retinoider |
| WO2017201200A1 (en) | 2016-05-19 | 2017-11-23 | Orphagen Pharmaceuticals, Inc. | Therapeutic compositions containing rar-alpha antagonists |
| DE102016123286B4 (de) | 2016-12-01 | 2019-03-07 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Verfahren und Vorrichtung zur Georeferenzierung von Luftbilddaten |
| EP3709990A4 (en) * | 2017-11-17 | 2021-12-01 | The Regents of the University of California | MANIPULATION OF THE RETIC ACID SIGNAL PATH |
| CN114041070B (zh) | 2018-11-19 | 2024-03-08 | 棱镜传感器公司 | 边缘式光子计数检测器 |
| US12492177B2 (en) | 2019-12-19 | 2025-12-09 | Orphagen Pharmaceuticals, Inc. | RAR-α compounds for inflammatory disease and male contraception |
-
2020
- 2020-12-17 US US17/786,399 patent/US12492177B2/en active Active
- 2020-12-17 EP EP20842449.9A patent/EP4077300A1/en active Pending
- 2020-12-17 CN CN202080097179.0A patent/CN115335367B/zh active Active
- 2020-12-17 AU AU2020408043A patent/AU2020408043A1/en active Pending
- 2020-12-17 JP JP2022537288A patent/JP7657223B2/ja active Active
- 2020-12-17 CA CA3165166A patent/CA3165166A1/en active Pending
- 2020-12-17 WO PCT/US2020/065719 patent/WO2021127250A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN115335367B (zh) | 2024-08-13 |
| CN115335367A (zh) | 2022-11-11 |
| AU2020408043A1 (en) | 2022-07-28 |
| US20230357175A1 (en) | 2023-11-09 |
| WO2021127250A1 (en) | 2021-06-24 |
| JP2023509372A (ja) | 2023-03-08 |
| US12492177B2 (en) | 2025-12-09 |
| EP4077300A1 (en) | 2022-10-26 |
| JP7657223B2 (ja) | 2025-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5592388B2 (ja) | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野 | |
| JP6122055B2 (ja) | 核内受容体結合剤 | |
| EP2215049B1 (en) | P2x3, receptor antagonists for treatment of pain | |
| JP5815237B2 (ja) | 核内受容体結合剤 | |
| TW202014186A (zh) | 作為核轉運調節劑之化合物及其用途 | |
| KR102055395B1 (ko) | 염증 질환의 예방 및 치료 | |
| JP7516047B2 (ja) | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 | |
| JP2009543872A (ja) | 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用 | |
| RU2521286C2 (ru) | Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани | |
| JP2022095809A (ja) | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法 | |
| JP2020534294A (ja) | μ−オピオイド受容体アゴニスト及びその調製方法及び医療分野におけるその使用 | |
| KR20190018486A (ko) | 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법 | |
| US12492177B2 (en) | RAR-α compounds for inflammatory disease and male contraception | |
| CA3217096A1 (en) | Contraceptive compounds and methods | |
| JP2020533337A (ja) | 重水素原子置換インドールホルムアミド誘導体、その調製方法、およびその医療用途 | |
| CN114712504A (zh) | 炎性病况的预防和治疗 | |
| EP2731924A1 (en) | Terpene analogues and uses thereof for treating neurological conditions | |
| WO2025140721A1 (zh) | 腙类化合物、其药物组合物及其应用 | |
| WO2025045124A1 (zh) | Soat1抑制剂及其应用 | |
| AU2001214046A1 (en) | Treatment of sexual dysfunction using bombesin antagonist | |
| WO2019022501A1 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A VASCULAR DISRUPTION AGENT AND AN IMMUNE CONTROL POINT INHIBITOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241213 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250523 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260106 |